The U.S. Food and Drug Administration approved Kalydeco® (ivacaftor) for infants as young as 1 month who have at least one copy of 97 mutations that have proven to be responsive to Kalydeco.
Site Search
Showing 1 - 3 of 3 results
Medicaid beneficiaries are encouraged to update their information with Medicaid to ensure continued coverage.
News
|
|
5 min read
The Cystic Fibrosis Foundation is providing additional funds to TB Alliance to advance the development of a compound that could be used to treat infections caused by nontuberculous mycobacteria.
News
|
|
2 min read